BioCentury
ARTICLE | Clinical News

CXA-201: Phase III started

August 8, 2011 7:00 AM UTC

Cubist began a double-blind, international Phase III trial to compare 1,500 mg IV CXA-201 given every 8 hours for 7 days vs. IV levofloxacin in about 775 patients. The company expects to begin a secon...